Recently, clinical trials of WT1 peptide-based immunotherapy have been conducted in various malignancies including renal cell carcinoma, multiple myeloma, acute myeloid leukemia, lung cancer, and MDS 42–47. This evidence concerns the gene WT1 and lung carcinoma.